<DOC>
	<DOCNO>NCT03093233</DOCNO>
	<brief_summary>Intracerebral hemorrhage [ ICH ] fear complication oral anticoagulation [ OAC ] , yet therapeutic strategy limit reflect overall weak guideline recommendation . Studies investigate acute intervention especially patient ICH take non-vitamin-K-oral-anticoagulants [ NOAC ] remain inconclusive . Further , acute management issue OAC-ICH patient ( hematoma evacuation surgery , prevention acute thromboembolic event , intraventricular fibrinolysis ) still need investigate . Therefore , observational study ( RETRACE-II ) represent follow-up investigation RETRACE ( German-wide Multicenter Analysis Oral Anticoagulant-associated Intracerebral Hemorrhage , study-period 2006-2010 , NCT01829581 ) , span study-period 2011 2015 19 participate tertiary care center nation-wide Germany . Data pool two RETRACE study , altogether include 2500 patient treat 22 center 10 year period allow statistically appropriate analysis different outcome .</brief_summary>
	<brief_title>Multicenter Analysis Oral Anticoagulant-associated ICH - Part Two</brief_title>
	<detailed_description>Stroke general one lead cause death disability industrialize world . Cardiac thrombo-embolisms major contributor ischemic infarction atrial fibrillation [ afib ] frequent underlie pathology . As prevalence afib constantly increase age population , establish therapy ( oral anticoagulation vitamin-K antagonist [ VKA ] non-vitamin-K-oral-anticoagulants [ NOAC ] ) increase alongside . Therefore , rate OAC-ICH expect increase simultaneously . OAC-ICH associated large ICH-volumes , increase frequency hematoma enlargement , bad clinical outcome compare primary spontaneous ICH . Nevertheless , limit evidence exists regard acute treatment strategy . For prevention hematoma enlargement VKA-ICH large observational cohort study ( n=1176 ) first time identify time window ( &lt; 4h ) INR level ( INR &lt; 1.3 ) within reversal alter coagulation may show reduce rate hematoma enlargement ( 1 ) . For NOAC-ICH small size investigation case report available address press question - reverse anticoagulation NOAC-ICH . Existing data even allow appropriate description NOAC-ICH patient term hematoma characteristic , re-bleeding rate , neurologic severity functional outcome . Due dilemma without available antidote ( except dabigatran ) reversal strategy intensely debate evidence base guideline recommendation exist . Further important treatment approach ICH-care ( ) hematoma evacuation surgery , ( ii ) early anticoagulation prophylaxis systemic thromboembolism , ( iii ) intraventricular fibrinolysis , investigate grow sub-population ( increase incidence ) vastly exclude randomize trial . Therefore , observational cohort study ( RETRACE-II ) try strengthen therapeutic evidence OAC-ICH treatment data-assessment 19 nation-wide tertiary care hospital Germany . Patients identify medical record diagnosis ICH concomitantly present intake VKA ( INR &gt; 1.5 ) know intake NOAC time period 20011-2015 . Only patient ICH associate OAC include , secondary cause i.e . tumor , trauma , vascular malformation aneurysms etc . exclude . Clinical data demographic , medical history , pre-ICH medication exposure laboratory result obtain medical chart , institutional database prospective registry , supplement structured interview review available medical record individual institution . Patient-derived follow-up information corroborate review pertinent medical record . An estimated total number great 1000 patient review investigation . In detail follow parameter evaluate : - prior medical history ( include CHADS-VASC-Score , HAS-Bled Score , vascular risk factor ) , - functional status prior admission ( mRS ) , - neurological admission status ( NIHSS , GCS ) , - imaging characteristic , - time interval : symptom onset admission , image , therapy initiation , - mode hemostatic therapy , - acute blood pressure management , - complication ( hemorrhagic- ischemic-events , infectious ) treatment ( surgical treatment , mode antithrombotic treatment prophylaxis systemic thromboembolism , intraventricular fibrinolysis , etc . ) , - mortality rate , - functional outcome ( mRS ) . Participating Centers ( upon Invitation ) : Klinikum Bad Hersfeld , Department Neurology , Germany . HELIOS Klinikum Berlin-Buch , Department Neurology , Germany . University Hospital Charité Berlin , Department Neurology , Germany . Klinikum Dortmund , Department Neurology , Germany . University Dresden , Department Neurology , Germany . Asklepios Klinik Hamburg Altona , Department Neurology , Germany . Heidelberg University Hospital , Department Neurology , Germany . University Jena , Department Neurology , Germany . Klinikum Koblenz , Department Neurology , Germany . University Cologne , Department Neurology , Germany . University Leipzig , Department Neurology , Germany . Klinikum der Stadt Ludwigshafen Rhein , Department Neurology , Germany . Johannes Wesling Medical Center Minden , Department Neurology , Germany . University Münster , Department Neurology , Germany . Klinikum Nürnberg , , Department Neurology , Germany . Klinikum Stuttgart , Department Neurology , Germany . University Ulm , Department Neurology , Germany . University Wuerzburg , Department Neurology , Germany . Funding : This study partly support research grant Johannes &amp; Frieda-Marohn Foundation ( FWN/Zo-Hutt/2011 ) ELAN fonds ( ELAN 12.01.04.1 ) , University Erlangen , Germany .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>VKAICH define effective use VKA INRvalue &gt; 1.5 hospital admission NOACICH define know treatment NOAC ICHonset ICH relate trauma , tumor , arteriovenous malformation , aneurysmal subarachnoid hemorrhage , acute thrombolysis , coagulopathies .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>